Scientific exchange · Dr. Ulrich Abbott

07 Mar 2026 · In person · Dr. Ulrich Abbott, Hôpital Pitié-Salpêtrière · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0082—

Capture insight from this engagement

Location: Hôpital Pitié-Salpêtrière
Therapeutic area: Oncology
Country: France
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Elderly / ECOG 2 patients
Comparator checkpoint monotherapy
Brain-metastasis subgroup data

Scientific content used

VOYAGE-1 pivotal data summary

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Scientific exchange with pathologist at Hôpital Pitié-Salpêtrière. Discussed elderly / ecog 2 patients, comparator checkpoint monotherapy, brain-metastasis subgroup data.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 4
Depth of exchange: 4
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0082

Audit history (0)

All create, update and approval events for this record

No audit events in sample data